Oncoinvent ASA: Oncoinvent appoints Dr Zuzana Jiráková Trnková as Chief Medical Officer to lead Phase 3 preparations for Radspherin[®]

Oslo, Norway - 28 October 2026 - Oncoinvent ASA (OSE: ONCIN), a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced the appointment of Zuzana Jiráková Trnková, MD, PhD, as Chief Medical Officer, effective November 4, 2026. Dr Jiráková Trnková succeeds Kari Myren, who will leave Oncoinvent to pursue a new opportunity outside drug discovery.

Dr Jiráková Trnková is a physician-scientist with more than 20 years of clinical development experience, primarily in oncology, covering first-in-human studies to pivotal Phase 3 trials and regulatory approval. She has expertise in alpha-emitting radiopharmaceuticals and has held senior leadership roles at Bayer, BioNTech and Highlight Therapeutics, most recently as Chief Medical Officer at Highlight, where she was responsible for clinical development, medical and regulatory strategy, and patient safety.

At Bayer, where she spent 13 years, she led global radiology clinical development and medical affairs, overseeing more than 100 people,and headed oncology clinical pharmacology, including radium-223 (Xofigo^®) and targeted thorium conjugates. She also led two pivotal Phase 3 trials supporting the approval of Gadovist^® for breast cancer detection.

At BioNTech, she served as Vice President of Clinical Research and Development, leading clinical development, operations and regulatory strategy across immuno-oncology, rare diseases, and infectious diseases, while building the company's clinical development organization and contributing to collaborations with major pharmaceutical partners.

She began her career in academia as a resident physician in internal medicine and hemato-oncology. Dr Jiráková Trnková holds an MD in general medicine and a PhD in immunology and molecular biology from Charles University in Prague.

"I am very pleased to welcome Zuzana to Oncoinvent. Her experience leading global pivotal Phase 3 trials through to approval, together with her work with alpha-emitting radiopharmaceuticals, will be highly valuable as we prepare Radspherin^® for Phase 3 development. I would also like to thank Kari for her important contribution to Oncoinvent, including taking Radspherin^® into the randomized Phase 2 trial in ovarian cancer, and wish her every success for the future," said Oystein Soug, Chief Executive Officer of Oncoinvent.

"Radspherin^® offers a distinctive approach to treating peritoneal disease," commented Zuzana Jiráková Trnková, incoming Chief Medical Officer of Oncoinvent. "I look forward to bringing my experience in oncology, late-stage clinical development and radiopharmaceuticals to the team, and to working closely with investigators and regulators as we prepare Radspherin^® for Phase 3 development to bring this potential new treatment closer to patients."

***